Strong Buy IOVA by Dec 24, 2026.

Alright, fellow autists, let's talk Iovance Biotherapeutics, this biotech play is decen in the cancer-killing game, pulling TIL therapy out of patients' own tumors to punch melanoma in the face. Amtagvi got the FDA thumbs-up back in 2024 for end-stage skin cancer, and now they're with Proleukin like a tag-team wrestling match against tumors. Revenue's up, Q3 2025 is at $67.5 million, up 13% from last quarter, with full-year guidance hitting $250-300 million in sales. But yeah, they're still bleeding …